Tabula Rasa Healthcare Inc. (NASDAQ:TRHC)‘s stock had its “buy” rating restated by stock analysts at Piper Jaffray Companies in a research note issued on Tuesday. They currently have a $29.00 price target on the stock. Piper Jaffray Companies’ price target points to a potential upside of 9.39% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Chardan Capital boosted their price objective on shares of Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Stifel Nicolaus reissued a “buy” rating and issued a $16.00 price objective on shares of Tabula Rasa Healthcare in a research note on Friday, July 14th. UBS AG boosted their price objective on shares of Tabula Rasa Healthcare from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, August 30th. ValuEngine raised shares of Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, Wells Fargo & Company cut shares of Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and upped their price target for the company from $17.00 to $21.00 in a research report on Thursday, September 7th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $25.57.

Tabula Rasa Healthcare (NASDAQ:TRHC) traded up 1.73% during midday trading on Tuesday, reaching $26.51. The company had a trading volume of 24,837 shares. Tabula Rasa Healthcare has a one year low of $10.39 and a one year high of $28.53. The stock’s 50 day moving average is $26.14 and its 200 day moving average is $26.14. The company’s market capitalization is $458.25 million.

Tabula Rasa Healthcare (NASDAQ:TRHC) last issued its quarterly earnings data on Monday, August 7th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 9.58%. The company had revenue of $29.70 million for the quarter, compared to analysts’ expectations of $27.84 million. The business’s quarterly revenue was up 32.6% on a year-over-year basis. Equities research analysts forecast that Tabula Rasa Healthcare will post $0.39 earnings per share for the current fiscal year.

WARNING: “Tabula Rasa Healthcare Inc. (TRHC) Given Buy Rating at Piper Jaffray Companies” was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/24/tabula-rasa-healthcare-inc-trhc-given-buy-rating-at-piper-jaffray-companies.html.

In other Tabula Rasa Healthcare news, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $17.21, for a total transaction of $137,680.00. Following the sale, the chief executive officer now owns 918,362 shares of the company’s stock, valued at $15,805,010.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 24,000 shares of company stock worth $527,920 in the last ninety days. Insiders own 45.80% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Hood River Capital Management LLC boosted its position in Tabula Rasa Healthcare by 7.5% during the second quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock valued at $12,420,000 after acquiring an additional 57,724 shares during the last quarter. Wellington Management Group LLP boosted its position in Tabula Rasa Healthcare by 37.2% during the first quarter. Wellington Management Group LLP now owns 782,142 shares of the company’s stock valued at $10,544,000 after acquiring an additional 212,164 shares during the last quarter. Vanguard Group Inc. boosted its position in Tabula Rasa Healthcare by 13.4% during the second quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock valued at $3,566,000 after acquiring an additional 27,997 shares during the last quarter. Boston Partners boosted its position in Tabula Rasa Healthcare by 17.1% during the second quarter. Boston Partners now owns 235,180 shares of the company’s stock valued at $3,540,000 after acquiring an additional 34,360 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Tabula Rasa Healthcare by 97.4% during the second quarter. Northern Trust Corp now owns 95,862 shares of the company’s stock valued at $1,443,000 after acquiring an additional 47,306 shares during the last quarter. 27.89% of the stock is currently owned by institutional investors and hedge funds.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.